J. Goldman & Co’s Aldeyra Therapeutics ALDX Stock Holding History

J. Goldman & Co’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-108,000	Closed	-$906K	–	359
2023 Q2	$906K	Buy	+108,000	New	+$1.06M	0.03%	259
2022 Q4	–	Sell	-270,000	Closed	-$1.44M	–	364
2022 Q3	$1.44M	Buy	+270,000	New	+$1.62M	0.07%	235

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's ALDX Position: Q4 2023 in Review

J. Goldman & Co sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 27,000 shares — an estimated $180K sold.

J. Goldman & Co first reported a position in ALDX in Q3 2022 and held it in 5 quarters. The position peaked at $4.57M in Q4 2022. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

J. Goldman & Co reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 27,000 Aldeyra Therapeutics shares in Q4 2023, an estimated $180K.
J. Goldman & Co first reported a position in Aldeyra Therapeutics in Q3 2022 and held it in 5 quarters.
J. Goldman & Co's Aldeyra Therapeutics position peaked at $4.57M in Q4 2022.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.